Payload Information
General Information of This Payload
| Payload ID | PAY0EJPTW |
|||||
|---|---|---|---|---|---|---|
| Name | KR1020250002133A Trastuzumab-C-8 Payload |
|||||
| Synonyms |
KR1020250002133A Trastuzumab-C-8 Payload
Click to Show/Hide
|
|||||
| Structure |
|
|||||
| Formula | C39H67N5O7 |
|||||
| Isosmiles | CC[C@@H]([C@H](N(C)C([C@@H](NC([C@@H](NC)C(C)C)=O)C(C)C)=O)[C@H](OC)CC(N1CCCC1[C@H](OC)[C@H](C(N[C@H](C)[C@@H](O)C2=CC=CC=C2)=O)C)=O)C |
|||||
| PubChem CID | ||||||
| InChI |
InChI=1S/C39H67N5O7/c1-13-25(6)34(43(10)39(49)33(24(4)5)42-38(48)32(40-9)23(2)3)30(50-11)22-31(45)44-21-17-20-29(44)36(51-12)26(7)37(47)41-27(8)35(46)28-18-15-14-16-19-28/h14-16,18-19,23-27,29-30,32-36,40,46H,13,17,20-22H2,1-12H3,(H,41,47)(H,42,48)/t25-,26+,27+,29?,30+,32-,33-,34-,35+,36+/m0/s1
|
|||||
| InChIKey |
DASWEROEPLKSEI-FQOVWFDBSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
717.993 |
Polar area |
149.54 |
||
Complexity |
1195.6522 |
xlogp Value |
3.5298 |
|||
Heavy Count |
51 |
Rot Bonds |
20 |
|||
Hbond acc |
8 |
Hbond Donor |
4 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
Trastuzumab-C-8 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.112 nM
|
High HER2 expression (HER2 +++) | ||
| Method Description |
Trastuzumab-C-8 was tested in HCC1954,80ul,18ᆬh
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.25 nM
|
High HER2 expression (HER2 +++) | ||
| Method Description |
Trastuzumab-C-8 was tested in NCI-N87,80ul,18ᆬh
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
374.766 nM
|
High HER2 expression (HER2 +++) | ||
| Method Description |
Trastuzumab-C-8 was tested in NCI-H358,80ul,18ᆬh
|
||||
| In Vitro Model | Minimally invasive lung adenocarcinoma | NCI-H358 cells | CVCL_1559 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
17.72 nM
|
High HER2 expression (HER3 +++) | ||
| Method Description |
Trastuzumab-C-8 was tested in HCC1954 and PBMC,50ul,24h
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Emax (TNF-a) |
1836.92 pg/mL
|
High HER2 expression (HER4 +++) | ||
| Method Description |
Trastuzumab-C-8 was tested in HCC1954 and PBMC,50ul,24h
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||